PAR vs TOST vs RSKD vs RLAY vs CTLP

For growth investors, Relay Therapeutics, Inc.

(RLAY) is the stronger pick with 53. 4% revenue growth year-over-year, versus 5. 2% for Riskified Ltd. (RSKD). Cantaloupe, Inc. (CTLP) offers the better valuation at 13. 0x trailing P/E (27. 3x forward), making it the more compelling value choice. Analysts rate PAR Technology Corporation (PAR) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cantaloupe, Inc.

(CTLP) is the cheapest at 13. 0x versus Toast, Inc. at 52. 4x. On forward P/E, Riskified Ltd. is actually cheaper at 20. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Cantaloupe, Inc.

(CTLP) delivered a total return of +1. 1%, compared to -81. 4% for Riskified Ltd. (RSKD). Over 10 years, the gap is even starker: PAR returned +167. 3% versus RSKD's -81. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cantaloupe, Inc.

(CTLP) is the lower-risk stock at 0. 38β versus Relay Therapeutics, Inc. 's 1. 77β — meaning RLAY is approximately 369% more volatile than CTLP relative to the S&P 500. On balance sheet safety, Toast, Inc. (TOST) carries a lower debt/equity ratio of 2% versus 49% for PAR Technology Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Relay Therapeutics, Inc.

(RLAY) is pulling ahead at 53. 4% versus 5. 2% for Riskified Ltd. (RSKD). On earnings-per-share growth, the picture is similar: Toast, Inc. grew EPS 1639% year-over-year, compared to -1392. 9% for PAR Technology Corporation. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cantaloupe, Inc.

(CTLP) is the more profitable company, earning 21. 3% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 21. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTLP leads at 7. 4% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — RLAY leads at 76. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Riskified Ltd.

(RSKD) trades at 20. 8x forward P/E versus 28. 3x for PAR Technology Corporation — 7. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RLAY: 72. 7% to $21. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cantaloupe, Inc.

(CTLP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 38), +141. 9% 10Y return). Relay Therapeutics, Inc. (RLAY) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTLP: +141. 9%, RLAY: -64. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PAR (Technology) and TOST (Technology) and RSKD (Technology) and RLAY (Healthcare) and CTLP (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PAR is a small-cap high-growth stock; TOST is a mid-cap high-growth stock; RSKD is a small-cap quality compounder stock; RLAY is a small-cap high-growth stock; CTLP is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.